Olympus Global Homepage
日本語
ABOUT US
1.9 million New Incidents of Colon Cancer*
*Source: GLOBOCAN 2020
50 millionColonoscopies PerformedWorldwide*
*Numbers for the US, Canada, Germany, France, Italy, Spain, the UK, Japan, China, South Korea, Australia and India. As of 2019
100Diseases or Conditions Treated
At Olympus we have versatile medical deviceswith the ability to treat approximately100* diseases or conditions
*As of March 2022
TOP 4Cancers Treated
Olympus provides products/solutions for lung, stomach, colon and prostate cancers - the top 4* highest incidence of cancers *Top 4 highest incidence of caners excluding breast cancer, as of March 2022.Source: GLOBOCAN 2020
31,557Employees Worldwide*
39Countries or Regions*
¥737.1bnTotal MedicalRevenue FY2022*
Medical Business occupiesthe largest part of our revenue
*Figures are fiscal year revenues as of March 2022
70%Global Market Share*
Olympus is the leader ingastrointestinal endoscopic equipment
*As of Nov 2021
70%Olympus R&D*expenditures
are dedicated to the medical business.
*Research and development for fiscal year ending March 2022.
291Awards
Since 1966, Olympus has been consistentlyhonored with national and international designawards for its innovative product designs.*
17,000Patents
across our product portfolio*
CO2“0”Net zero CO2 emissions by 2030
We set as a target of achieving net zero CO2 emissions by 2030 from our site operations
TOP 100Global Innovator
Since 2012 to 2020, and in 2022, Olympus has beenawarded as one of the top 100 mostinnovative companies in the world.https://clarivate.com/top-100-innovators/